Immunicum AB (publ) Publishes the Annual Report for 2017
April 03 2018 - 6:00AM
Press Release
3 April 2018
Immunicum AB (publ) Publishes the Annual Report for 2017
Immunicum AB
(publ; IMMU.ST), today announced that its Annual Report for 2017 is
now available on the company's website,
www.immunicum.com.
The Annual Report will be sent by
regular mail to shareholders and other interested parties upon
special request. For further information, please contact the
company by telephone +46 (0) 31 41 50 52 or e-mail,
info@immunicum.com.
This information
is information that Immunicum is obliged to make public pursuant to
the Securities Markets Act. The information was submitted for
publication, through the agency of the contact person set out
below, at 12:00 CEST on 3 April 2018.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 76 243 6810
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne
Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ) Immunicum is establishing a
unique immuno-oncology approach through the development of
allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the
patient's own immune system to fight cancer. The company's lead
product ilixadencel, consisting of pro-inflammatory allogeneic
dendritic cells, has the potential to become a backbone component
of modern cancer combination treatments in a variety of solid tumor
indications. Founded and based in Sweden, Immunicum is publicly
traded on the Nasdaq Stockholm www.immunicum.com |
20180403_Annual Report Announcement
PR_ENG_FINAL
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024